Header Logo

Connection

HASHEM EL-SERAG to Non-alcoholic Fatty Liver Disease

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Non-alcoholic Fatty Liver Disease.
HASHEM EL-SERAG
Connection Strength
10.242
Non-alcoholic Fatty Liver Disease
  1. A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol. BMC Health Serv Res. 2025 May 06; 25(1):645.
    View in: PubMed
    Score: 0.631
  2. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.588
  3. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.563
  4. Association of Diet Quality with Metabolic (Dysfunction) Associated Fatty Liver Disease in Veterans in Primary Care. Nutrients. 2023 Jun 01; 15(11).
    View in: PubMed
    Score: 0.552
  5. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
    View in: PubMed
    Score: 0.548
  6. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.541
  7. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
    View in: PubMed
    Score: 0.528
  8. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023 05; 21(5):1252-1260.e5.
    View in: PubMed
    Score: 0.519
  9. Rational HCC screening approaches for patients with NAFLD. J Hepatol. 2022 01; 76(1):195-201.
    View in: PubMed
    Score: 0.490
  10. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.440
  11. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2020 05; 158(6):1822-1830.
    View in: PubMed
    Score: 0.438
  12. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.397
  13. Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis? Aliment Pharmacol Ther. 2018 02; 47(3):437-438.
    View in: PubMed
    Score: 0.382
  14. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):301-8.e1-2.
    View in: PubMed
    Score: 0.322
  15. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023 08; 20(8):487-503.
    View in: PubMed
    Score: 0.136
  16. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.133
  17. Prevalence and risk factors of nonalcoholic fatty liver disease in a general population, the HUNT study. Scand J Gastroenterol. 2023 05; 58(5):505-511.
    View in: PubMed
    Score: 0.133
  18. NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? Semin Liver Dis. 2022 11; 42(4):465-474.
    View in: PubMed
    Score: 0.132
  19. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.129
  20. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022 10; 19(10):638-651.
    View in: PubMed
    Score: 0.129
  21. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022 07 05; 34(7):969-977.e2.
    View in: PubMed
    Score: 0.129
  22. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep. 2022 04 05; 12(1):5695.
    View in: PubMed
    Score: 0.127
  23. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022 06; 75(6):1420-1428.
    View in: PubMed
    Score: 0.125
  24. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021 11; 161(5):1657-1669.
    View in: PubMed
    Score: 0.123
  25. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring). 2021 09; 29(9):1401-1412.
    View in: PubMed
    Score: 0.122
  26. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 09; 44(9):2162-2172.
    View in: PubMed
    Score: 0.121
  27. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
    View in: PubMed
    Score: 0.121
  28. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021 04; 18(4):223-238.
    View in: PubMed
    Score: 0.117
  29. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 01; 73 Suppl 1:4-13.
    View in: PubMed
    Score: 0.116
  30. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.115
  31. External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Dig Dis Sci. 2021 07; 66(7):2387-2393.
    View in: PubMed
    Score: 0.114
  32. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
    View in: PubMed
    Score: 0.111
  33. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5.
    View in: PubMed
    Score: 0.101
  34. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019 01; 156(2):477-491.e1.
    View in: PubMed
    Score: 0.100
  35. Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPa-p300 Axis. Cell Rep. 2018 08 07; 24(6):1597-1609.
    View in: PubMed
    Score: 0.099
  36. Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clin Gastroenterol Hepatol. 2017 12; 15(12):1965-1967.
    View in: PubMed
    Score: 0.091
  37. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci. 2017 02; 62(2):526-533.
    View in: PubMed
    Score: 0.088
  38. Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2017 02; 15(2):310-312.
    View in: PubMed
    Score: 0.087
  39. Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Dig Dis Sci. 2016 06; 61(6):1714-20.
    View in: PubMed
    Score: 0.082
  40. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Jan; 14(1):124-31.e1.
    View in: PubMed
    Score: 0.080
  41. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014 Oct; 40(8):949-54.
    View in: PubMed
    Score: 0.075
  42. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):594-601.e1.
    View in: PubMed
    Score: 0.075
  43. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015 Jan; 110(1):10-4.
    View in: PubMed
    Score: 0.074
  44. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1342-1359.e2.
    View in: PubMed
    Score: 0.066
  45. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.030
  46. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016 Mar; 43(5):621-30.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.